Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for RAS-addicted cancers. The company's core mission is to revolutionize treatment for patients suffering from these cancers through the discovery, development, and delivery of innovative, targeted medicines. Revolution Medicines maintains its headquarters in Redwood City, California, United States.

The company's research and development pipeline is primarily focused on RAS(ON) Inhibitors, which are designed to suppress various oncogenic variants of RAS proteins. Key investigational therapies currently in clinical development include daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor. Additionally, RMC-5127, a RAS(ON) G12V-selective inhibitor, is also in clinical trials. These therapies aim to address cancers driven by RAS mutations, which are prevalent in pancreatic, lung, and colorectal cancers.

In recent news, on May 1, 2026, the U.S. Food and Drug Administration (FDA) granted expanded access to Revolution Medicines' investigational pancreatic cancer drug, daraxonrasib (RMC-6236), for patients with metastatic pancreatic ductal adenocarcinoma. This authorization allows for the early use of the drug outside of traditional clinical trials, highlighting the critical need for new treatments for this aggressive disease. Daraxonrasib has demonstrated promising late-stage trial data, showing a significant improvement in overall survival for previously treated patients compared to standard chemotherapy. Mark A. Goldsmith, M.D., Ph.D., leads the company as its Chief Executive Officer and Chairman. Revolution Medicines is strategically positioned as a clinical-stage oncology company specializing in direct RAS(ON) inhibition.